News articles about Mirna Therapeutics (NASDAQ:MIRN) have trended positive on Tuesday, according to AlphaOne. The research group, a division of Accern, identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mirna Therapeutics earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also gave news coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Shares of Mirna Therapeutics (NASDAQ:MIRN) traded down 2.87% during midday trading on Tuesday, hitting $2.03. 13,988 shares of the company traded hands. The stock’s market capitalization is $42.34 million. Mirna Therapeutics has a 52 week low of $1.12 and a 52 week high of $4.94. The company has a 50-day moving average price of $2.17 and a 200-day moving average price of $1.86.

Several equities research analysts recently weighed in on MIRN shares. Zacks Investment Research downgraded shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price target on shares of Mirna Therapeutics in a research report on Thursday, April 13th. Six research analysts have rated the stock with a hold rating, The stock has an average rating of “Hold” and a consensus target price of $3.63.

ILLEGAL ACTIVITY NOTICE: “Mirna Therapeutics (MIRN) Receiving Positive News Coverage, Study Shows” was published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc and related companies with's FREE daily email newsletter.